HeartBeat.bio is an early-stage drug discovery company focused on the development of a high-throughput fully human 3D screening platform for heart diseases. The technology has the potential to radically change the current cardiovascular drug discovery paradigm, leading to higher success rates in clinical trials, reduced cost and time for compound development. HeartBeat.bio’s business strategy is to leverage its screening technology into multiple R
R&D:Our core technology is based on the world-wide first self-organizing cardiac organoids (Cardioids) which resemble the human physiology of a heart chamber in a way that allows for the cost-efficient and large scale in-vitro analysis of crucial clinical parameters associated with cardiac diseases and cardiotoxicity. We will initially focus our R